Treatments
Monoclonal Antibodies
Bebtelovimab has not been approved, but has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
The dosage in adults (18 years and older) and pediatric patients (≥12 years of age and weighing at least 40 kg) is bebtelovimab 175 mg. Bebtelovimab should be administered as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset. Under this EUA, bebtelovimab must be administered as a single intravenous injection over at least 30 seconds.
Patients must be clinically monitored during administration and observe patients after IV infusion.

Influenza A and B
Influenza A and B are viruses that cause symptoms of respiratory tract but can also cause various other symptoms. Those symptoms include headache, fever, body-ache, joint pain, nausea, vomiting, diarrhea, etc. If tests confirm that you have Influenza A or B, a prescription medication can help treat your symptoms. Our physician can prescribe an anti-viral medication to stop the progression of the flu and get you back to normal. The prescription works best if taken within the first 72 hours of your symptoms. It’s best to test and be treated early.
Strep Throat


STI
Urinary Tract Infection
Urinary tract infection (UTI)- if detected early, a UTI can be treated with a 3 day course of antibiotics. Delayed diagnosis can lead to more serious illness and need for longer treatment. Discuss your history of UTI and allergies with our providers to be certain you are prescribed the best antibiotic for you.
